Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis


Last updated date
Study Location
Tokyo, , , Japan


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients receiving Tofacitinib (Xeljanz)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Not Applicable


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid ArthritisStudy Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis NCT00141830
  1. Largo, Florida
  2. Palm Harbor, Florida
  3. Sarasota, Florida
  4. Boise, Idaho
  5. Kansas City, Kansas
  6. Frederick, Maryland
  7. Albuquerque, New Mexico
  8. Charlotte, North Carolina
  9. Duncansville, Pennsylvania
  10. Austin, Texas
  11. Dallas, Texas
  12. San Antonio, Texas
  13. Spokane, Washington
  14. La Crosse, Wisconsin
  15. Penticton, British Columbia
  16. Newmarket, Ontario
  17. Toronto, Ontario
  18. Montréal, Quebec
  19. Trois-Rivières, Quebec
  20. Saskatoon, Saskatchewan
  21. Quebec,
  22. Budapest,
  23. Békéscsaba,
  24. Veszprém,
  25. Brescia,
  26. Genova,
  27. Pavia,
  28. Roma,
  29. Siena,
  30. Jalisco, Guadalajara
  31. Delegacion Cuahutemoc,
  32. Andalucia,
  33. Castilla la Mancha,
  34. Comunidad Valenciana,
  35. Madrid,
18 Years+
Rheumatoid ArthritisStudy Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 NCT01059864
  1. Birmingham, Alabama
  2. Huntsville, Alabama
  3. Gilbert, Arizona
  4. Scottsdale, Arizona
  5. Upland, California
  6. Jacksonville, Florida
  7. Dayton, Ohio
  8. Mayfield Village, Ohio
  9. Greenville, South Carolina
  10. Allen, Texas
  11. Seoul,
  12. Seoul,
  13. Seoul,
  14. Seoul,
  15. Seoul,
18 Years+
Rheumatoid ArthritisEffects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) NCT01164579
  1. Gilbert, Arizona
  2. Huntington Beach, California
  3. Upland, California
  4. Ormond Beach, Florida
  5. Pinellas Park, Florida
  6. St. Petersburg, Florida
  7. Oklahoma City, Oklahoma
  8. Allen, Texas
  9. Buenos Aires,
  10. Buenos Aires,
  11. Buenos Aires,
  12. Valdivia, Region XIV
  13. Osorno, X Region
  14. Split,
  15. Zagreb,
  16. Hostivice,
  17. Praha 11 - Chodov,
  18. Praha 1,
  19. Praha 1,
  20. Praha 2,
  21. Uherske Hradiste,
  22. Zlin,
  23. Zlin,
  24. Balatonfured,
  25. Budapest,
  26. Budapest,
  27. Debrecen,
  28. Gyor,
  29. Mexico, D. F.
  30. Mexico, D.f.
  31. Mexico, Distrito Federal
  32. Chapultepec,
  33. Chihuahua,
  34. Mexico D.F.,
  35. San Luis Potosi,
  36. Bialystok,
  37. Poznan,
  38. Torun,
  39. San Juan,
  40. San Juan,
18 Years+
Advanced Information
Descriptive Information
Brief Title Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis
Brief Summary

The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.

1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2? Long-term safety (particularly, malignant tumors and serious infections) and efficacy

Occurrences of malignant tumors and serious infections will be compared with a control group.

Detailed Description All the patients whom an investigator prescribes the Xeljanz or Standard of Care for rheumatoid arthritis should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment.
Condition Rheumatoid Arthritis
  • Drug: Tofacitinib (Xeljanz)
    5 mg Tablet BID
  • Drug: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
    Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
Study Groups/Cohorts
  • Tofacitinib (Xeljanz)
    Tablets 5 mg BID
    Intervention: Drug: Tofacitinib (Xeljanz)
  • Standard of Care
    Standard of Care for Rheumatoid Arthritis
    Intervention: Drug: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Active, not recruiting
Actual Enrollment
 (submitted: September 9, 2019)
Original Estimated Enrollment
 (submitted: August 27, 2013)
Estimated Study Completion Date December 15, 2020
Estimated Primary Completion Date December 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • All patients receiving Tofacitinib (Xeljanz)

Exclusion Criteria:

Not Applicable

Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Japan
Removed Location Countries  
Administrative Information
NCT Number NCT01932372
Other Study ID Numbers A3921194
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date November 2019